Retatrutide
    Pricing

    Retatrutide Price Prediction: Launch Cost

    What will retatrutide cost when it hits the market -- and how to access it affordably today.

    Last updated: April 1, 2026-10 min read

    With retatrutide showing the highest weight loss of any drug in clinical trials, the question on everyone's mind is: how much will it cost? Based on industry patterns and Eli Lilly's pricing strategy, here is what experts predict.

    Price Prediction Analysis

    Estimated Pricing

    ScenarioMonthly CostAnnual CostRationale
    Low estimate$1,100$13,200Competitive with Zepbound
    Mid estimate$1,350$16,200Premium for superior efficacy
    High estimate$1,500$18,000Flagship pricing for best-in-class
    Compounded (Trimi)Contact usSignificantly lessAvailable now

    Pricing Factors

    • Superior efficacy: 24.2% weight loss justifies premium over tirzepatide (22.5%)
    • Lilly's strategy: Zepbound launched at ~$1,060 -- lower than expected; may repeat
    • Competition: Semaglutide and tirzepatide create competitive pressure
    • Insurance dynamics: Higher price with patient assistance vs lower list price
    • Market size: 100M+ Americans with obesity represent massive potential volume

    Affordable Access Now

    You do not need to wait for brand-name launch. Trimi offers compounded retatrutide today, along with compounded semaglutide ($99/mo) and tirzepatide ($125/mo). Our physicians help determine if retatrutide is right for you.

    Why Wait? Access Retatrutide Now

    Trimi offers all three GLP-1 medications at affordable compounded pricing.

    Explore Options

    Medical Disclaimer

    Price predictions are estimates based on industry analysis and are not guaranteed. Retatrutide is investigational. Consult your healthcare provider.

    More on retatrutide

    Retatrutide Insurance Prediction

    Will insurers cover it?

    Retatrutide Compounding Future

    Compounding availability

    Retatrutide Generic Timeline

    When will generics come?

    Compounding vs Manufacturing

    Why compounding costs less

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the published clinical evidence show for retatrutide?

    Peer-reviewed evidence: Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023). Trimi is preparing for launch; compounded availability depends on FDA-cleared compounding pathways. Results vary by individual; eligibility is determined by a licensed clinician.

    Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. — Jastreboff et al. Phase 2 trial, NEJM 2023
    Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. — Rosenstock et al. Phase 2 T2D trial, Lancet 2023

    Key Takeaways

    • Retatrutide 12 mg produced a mean body weight reduction of approximately 24.2% at 48 weeks in adults with obesity in a Phase 2 trial — the highest published mean weight reduction for any GLP-1-class agent in obesity to date. (Source: Jastreboff et al. Phase 2 trial, NEJM 2023)
    • Retatrutide 12 mg reduced HbA1c by approximately 2.02 percentage points at 36 weeks in patients with type 2 diabetes, compared with 1.41 points on dulaglutide 1.5 mg. (Source: Rosenstock et al. Phase 2 T2D trial, Lancet 2023)
    • Retatrutide is investigational and not FDA-approved as of publication. Trial findings reported here are from Phase 2 / Phase 3 studies in peer-reviewed sources cited below.
    • Per KFF analysis (2024), commercial-plan coverage of GLP-1 medications specifically for obesity (vs type 2 diabetes) remains highly variable: approximately 19% of large employers offer GLP-1 anti-obesity coverage, often with strict BMI thresholds, prior-authorization requirements, and step-therapy mandates. (Source: KFF Issue Brief, 2024)
    • Eligibility requires evaluation by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Dose titration over weeks improves tolerability. Severe gastrointestinal symptoms may cause dehydration and increase acute kidney injury risk.
    • This is general information based on the cited evidence, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history, BMI, and comorbidities.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: January 23, 2026

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Arrived within 24 hours. Easy to use. Comes with everything. The year is so worth it.

    Outcome: Same-day delivery experience

    — Veronica LarimoreFacebook
    It's only been 2 weeks since I've been taking the VialsRx meds from Trimi. The medication showed up pretty quickly (about 4 days after getting approval from Trimi prescriber) and I received 3 vials for my first 3 months on the subscription. For the price and convenience my take is that Trimi and VialsRx is good.

    Outcome: 4-day delivery; 3 vials for first 3 months; price + convenience verdict positive

    — u/CSWB101Reddit (r/TirzepatideRX)
    See all community reviews →

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2301972
    2. Rosenstock J, Frias J, Jastreboff AM, et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet.Read StudyDOI: 10.1016/S0140-6736(23)01053-X
    3. ClinicalTrials.gov (2024). A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Are Overweight (TRIUMPH-1) — NCT05929066. ClinicalTrials.gov.Read Study
    4. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    5. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    6. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    GLP-1

    Retatrutide Price Prediction

    Analysis of when generic or biosimilar retatrutide may become available. Covers patent landscape, biosimilar development timeline, and why compounding provides affordable access decades before generic

    10 minRead More
    GLP-1

    Buy Tirzepatide in Texas

    Buy compounded semaglutide online in Texas for $99/month. Learn about Texas telehealth laws, compounding pharmacy access, and how to start affordable GLP-1 weight loss treatment.

    10 minRead More
    GLP-1

    Retatrutide Injection 2026: Once-Weekly Dose Guide (6-Day Half-Life)

    Step-by-step retatrutide injection: 6-day half-life, once-weekly dosing, site rotation, and how to time shots for fewer side effects and better weight loss results.

    10 minRead More
    GLP-1

    Semaglutide 0.25mg Starting Dose

    Guide to semaglutide 0.5mg dose increase. Learn what to expect at the first titration step, typical side effects, weight loss results, and when to advance to 1.0mg.

    10 minRead More

    Start your GLP-1 journey — from $99/mo

    Get Started